Fig. 4.

Protein expression profiles and prognostic values of LanCL2 and EGFR in GBM samples of tumor banks. A Frequencies of LanCL2 and EGFR protein overexpression in GBM samples of our tumor banks. B, C Relative expression of LanCL2 and EGFR in GBM samples was evaluated by measurement of density of immunoblotting bands. P values were determined by Mann–Whitney U test. ***p < 0.001. D, E Relative expression of LanCL2 and EGFR in newly diagnosed and relapsing GBM samples. Grade I gliomas were used for comparison, and GAPDH was served as the endogenous control. P values were determined by Kruskal–Wallis One-Way ANOVA and Dunn’s multiple comparisons. *p < 0.05; **p < 0.01. F Representative immunoblots of LanCL2 and EGFR protein expression in newly diagnosed and relapsing GBM specimens. G Person’s correlation analysis showed that protein expression of LanCL2 and EGFR was not significantly correlated. H Chi-square test showed the correlations between the protein expression of LanCL2 & EGFR and IDH1/2 mutation, MGMT methylation and TERT promoter mutation. I, J Protein overexpression of LanCL2 and EGFR was not significantly correlated with OS of GBM patients